DDInter1610 DDInter448
Rivastigmine is a parasympathomimetic or cholinergic agent for the treatment of mild to moderate dementia of the Alzheimer's type. Rivastigmine is a cholinesterase inhibitor that inhibits both butyrylcholinesterase and acetylcholinesterase.
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used to detect ALK and ROS1 rearrangements.
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) is bound by {v} (Compound) Crizotinib
Rivastigmine {u} (Compound) upregulates {v} (Gene) ST6GALNAC2
ST6GALNAC2 {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Rivastigmine {u} (Compound) upregulates {v} (Gene) MELK
MELK {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Rivastigmine {u} (Compound) downregulates {v} (Gene) GTPBP8
GTPBP8 {u} (Gene) is downregulated by {v} (Compound) Crizotinib
Rivastigmine {u} (Compound) causes {v} (Side Effect) Respiratory failure
Respiratory failure {u} (Side Effect) is caused by {v} (Compound) Crizotinib
Rivastigmine {u} (Compound) resembles {v} (Compound) Pyridostigmine
Pyridostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Rivastigmine {u} (Compound) resembles {v} (Compound) Neostigmine
Neostigmine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Crizotinib
Rivastigmine {u} (Compound) binds {v} (Gene) CYP3A4
CYP3A4 {u} (Gene) covaries with {v} (Gene) PTK2B
PTK2B {u} (Gene) is bound by {v} (Compound) Crizotinib
Rivastigmine {u} (Compound) upregulates {v} (Gene) ST6GALNAC2
ST6GALNAC2 {u} (Gene) is regulated by {v} (Gene) IGF1R
IGF1R {u} (Gene) is bound by {v} (Compound) Crizotinib
Rivastigmine {u} (Compound) upregulates {v} (Gene) GDPD5
GDPD5 {u} (Gene) is regulated by {v} (Gene) PPOX
PPOX {u} (Gene) is upregulated by {v} (Compound) Crizotinib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Rivastigmine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is upregulated by Crizotinib (Compound)
Rivastigmine (Compound) upregulates MELK (Gene) and MELK (Gene) is downregulated by Crizotinib (Compound)
Rivastigmine (Compound) downregulates GTPBP8 (Gene) and GTPBP8 (Gene) is downregulated by Crizotinib (Compound)
Rivastigmine (Compound) causes Respiratory failure (Side Effect) and Respiratory failure (Side Effect) is caused by Crizotinib (Compound)
Rivastigmine (Compound) resembles Pyridostigmine (Compound) and Pyridostigmine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Rivastigmine (Compound) resembles Neostigmine (Compound) and Neostigmine may cause a moderate interaction that could exacerbate diseases when taken with Crizotinib
Rivastigmine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) covaries with PTK2B (Gene) and PTK2B (Gene) is bound by Crizotinib (Compound)
Rivastigmine (Compound) upregulates ST6GALNAC2 (Gene) and ST6GALNAC2 (Gene) is regulated by IGF1R (Gene) and IGF1R (Gene) is bound by Crizotinib (Compound)
Rivastigmine (Compound) upregulates GDPD5 (Gene) and GDPD5 (Gene) is regulated by PPOX (Gene) and PPOX (Gene) is upregulated by Crizotinib (Compound)